Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436-1446. McMurray JJV, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med.

Objective To assess the efficacy and safety of the sodium-glucose cotransporter 2 inhibitor dapagliflozin in participants with metabolic dysfunction-associated steatohepatitis (MASH). Design ...

JSW MG Motor India has introduced the MY2025 Astor, claiming that it is now the only 1.5-litre mid-size SUV to offer both a 10-inch infotainment screen and a panoramic sunroof within a price range ...

AstraZeneca welcomed NICE’s decision, which expands access beyond previous eligibility criteria set in 2022. It aligns with a recent acceptance by the Scottish Medicines Consortium (SMC) for the same ...

ZOLADEX 10.8 mg contains the active ingredient goserelin acetate. ... AstraZeneca Pty Ltd ABN 54 009 682 311 66 Talavera Road MACQUARIE PARK NSW 2113. Telephone:- 1800 805 342.

• For BSX BSX, we notice a put option trade that happens to be bullish, expiring in 371 day(s) on June 18, 2026.This event was a transfer of 1500 contract(s) at a $100.00 strike. The total cost ...

Limited evidence exists to support the simultaneous initiation of sodium–glucose cotransporter-2 inhibitors and finerenone, a nonsteroidal mineralocorticoid receptor antagonist, in persons with ...

Originally designed as glucose-lowering medications, SGLT2 inhibitors provide benefits across the cardio-renal-metabolic ...

AstraZeneca’s Forxiga recommended by NICE for wider chronic kidney disease use. An estimated 7.2 million people in the UK are living with the progressive condition. AstraZeneca (AZ) has announced that ...

On the basis of phase 2 studies, trastuzumab deruxtecan was approved for patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic gastric cancer or gastroesophageal ...

On ASCO Day 3, AstraZeneca is dominant (again), ... 2-10 Users. $300. Annually per user. $300/year Get Started. $300 Annually per user. View All Plans. To read the rest of this story subscribe to ...